Boswellia serrata extract for the treatment of collagenous colitis. A double-blind, randomized, placebo-controlled, multicenter trial
Background and aims
The objective of this study was to investigate the effect of Boswellia serrata extract (BSE) on symptoms, quality of life, and histology in patients with collagenous colitis.
Materials and methods
Patients with chronic diarrhea and histologically proven collagenous colitis were randomized to receive either oral BSE 400 mg three times daily for 6 weeks or placebo. Complete colonoscopy and histology were performed before and after treatment. Clinical symptoms and quality of life were assessed by standardized questionnaires and SF-36. The primary endpoint was the percentage of patients with clinical remission after 6 weeks (stool frequency ≤3 soft /solid stools per day on average during the last week). Patients of the placebo group with persistent diarrhea received open-label BSE therapy for a further 6 weeks.
Thirty-one patients were randomized; 26 patients were available for per-protocol-analysis. After 6 weeks, the proportion of patients in clinical remission was higher in the BSE group than in the placebo group (per protocol 63.6%; 95%CI, 30.8–89.1 vs 26.7%, 95%CI, 7.7–55.1; p = 0.04; intention-to-treat 43.8% vs 26.7%, p = 0.25). Compared to placebo, BSE treatment had no effect on histology and quality of life. Five patients discontinued BSE treatment prematurely. Discontinuation was due to adverse events (n = 1), unwillingness to continue (n = 3), or loss to follow-up for unknown reasons (n = 1). Seven patients received open-label BSE therapy, five of whom achieved complete remission.
Our study suggests that BSE might be clinically effective in patients with collagenous colitis. Larger trials are clearly necessary to establish the clinical efficacy of BSE.
KeywordsMicroscopic colitis Collagenous colitis Boswellia serrata extract
- 16.Fine K, Ogunji F, Lee E, Lafon G, Tanzi M (1999) Randomized, double-blind placebo-controlled trial of bismuth subsalicylate for microscopic colitis (abstr.). Gastroenterology 166:A880Google Scholar
- 17.Baert F, Schmit A, D’Haens G, Dedeurwaerdere F, Louis E, Cabooter M, De Vos M, Fontaine F, Naegels S, Schurmans P, Stals H, Geboes K, Rutgeerts P (2002) Budesonide in collagenous colitis-a double-blind placebo-controlled trial with histological follow-up. Gastroenterology 122:20–25CrossRefPubMedGoogle Scholar
- 18.Miehlke S, Heymer P, Bethke B, Bästlein E, Meier E, Bartram HP, Wilhelms G, Lehn N, Dorta G, DeLarive J, Tromm A, Bayerdörffer E, Stolte M (2002) Budesonide treatment for collagenous colitis–a randomized, double-blind, placebo-controlled, multicenter trial. Gastroenterology 123:978–984CrossRefPubMedGoogle Scholar
- 29.Chande N, McDonald JW, Macdonald JK (2005) Interventions for treating collagenous colitis. Cochrane Database Syst Rev 19:CD003575Google Scholar
- 30.Madisch A, Miehlke S, Eichele E, Bethke B, Mrwa J, Wilhelms G, Debus M, Bästlein E, Kuhlisch E, Stolte M (2005) Boswellia Serrata Extract for the Treatment of collagenous colitis: a randomized, double-Blind, placebo-controlled, multicenter Trial. Gastroenterology 128:A581Google Scholar
- 32.Safayhi H, Mack T, Sabieray J Anazodo MI, Subramanian LR, Ammon HP (1992) Boswellic acids: novel, specific, nonredox inhibitors of 5-lipoxygenase. J Pharmacol Exp Ther 261/3:1143–1146Google Scholar
- 35.Krieglstein CF, Anthoni C, Rijcken EJ, Laukotter M, Spiegel HU, Boden SE, Schweizer S, Safayhi H, Senninger N, Schurmann G (2001) Acetyl-11-keto-beta-boswellic acid, a constituent of a herbal medicine from Boswellia serrata resin, attenuates experimental ileitis. Int J Colorectal Dis 16:88–95CrossRefPubMedGoogle Scholar